USD10
ANAB Shares
About AnaptysBioAnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).
USD10
ANAB Shares
About AnaptysBioAnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).
Stats
TRADING WINDOW
Closed
OPENS AT
Not enough data
MARKET CAP
$1.59B
OPEN PRICE
$65.16
LOW (1Y)
$12.21
HIGH (1Y)
$52.47
LOW (24H)
$55.61
HIGH (24H)
$66.28
VOLUME (24H)
$1.35M
435.78%
Price history
Time | Price | Change |
|---|---|---|
Today | $65.16 | |
1 Day | $57.40 | 0.00% |
1 Week | $61.02 | |
1 Month | $52.75 | |
1 Year | $18.59 |